secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2026-08-14T20:09:44+00:00
Accession:  0001628280-26-057112
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis prices 23M-share offering at $3.50, netting ~$75.1M
------------------------------------------------------------

- Offering of 23,000,000 shares at $3.50/share; underwriters have 30-day option for 3,450,000 additional shares.
- Net proceeds estimated at $75.1M after underwriting discounts and offering expenses.
- Closing expected August 17, 2026, subject to customary conditions.
- Proceeds to fund clinical trials, preclinical studies, regulatory filings, manufacturing, companion diagnostic, pre-commercial activities, and general corporate purposes.
- Underwriters: TD Securities, Guggenheim Securities, and Oppenheimer & Co. as representatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000162828026057112/0001628280-26-057112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000162828026057112/zntl-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-057112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer